Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
about
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasDasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case reportThe overwhelmingly positive response to Dasatinib of a patient with multiple blast crisis of chronic myeloid leukemia.Isolated central nervous system relapse in chronic myeloid leukemiaDasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Philadelphia chromosome-positive acute lymphoblastic leukemia.A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Targeted brain tumor treatment-current perspectivesPotential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma.Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.Central nervous system niche involvement in the leukemia.Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party oMyosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia.Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transportersPhase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeGleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavageDasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.Improving imatinib delivery to central nervous system.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.BCR gene disruption in a pilomyxoid astrocytoma.Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours.
P2860
Q24622397-6D6CDF10-9319-40BA-8882-1150FAF6BB62Q30243925-9CAAF3C3-59B4-42A5-B8AF-889A8B173AF7Q33861815-2171549F-A797-4DB1-8DED-9E98932C3F9BQ34231554-5FABD246-8512-4E2F-B58E-AAEB7C0CFD5BQ35167824-81BFC77A-2251-45BA-9D46-B6252EF27875Q35173962-83D04D06-E5C5-43A3-828A-1C31F5438B7CQ35279056-AB18CA7C-EFC0-4C10-BFDD-AE9C70776944Q35876347-FA65F07C-A09B-4244-9994-03979BDDC6BFQ36544862-F29C48A4-DF25-461F-BC6A-309BF97B73F4Q36986304-5BAF61D8-A4D0-4227-9BED-8EC14BF666A6Q37308322-ABDEF438-82CE-48C1-9AF8-03808090B57AQ37360559-F21FFBF0-4A43-4A4C-83E1-E27B438C195CQ37613888-4615D478-DAC4-4F30-A765-B89A6EED84EFQ37722753-B9FB1775-B78F-47D2-BB1D-5371606AE107Q37771246-8BE2B985-5ED0-48E2-A229-C0191C5CF4D3Q37875969-4009A2BE-3961-45AC-914C-6A1FF5E89506Q37928916-69A12D7D-46F2-4B4B-B56F-8CCB13D8A506Q38139571-264AB36E-8755-4A30-9AB8-7B86EC5DC321Q38176547-FAB9B9A6-4F9D-4DEE-9ECC-80A945BB9D79Q38269513-66ADED04-85C4-4853-902B-9148B794763EQ38560970-9B20952A-63D1-422A-BFC6-0A9BF0195C11Q38714657-CFA8EC7C-1D90-473E-BF01-8BBFE60D13EBQ38829019-5EDB875F-60FD-4C20-8799-756F88EED2B6Q38866851-8389ED8B-1B60-4B74-80AB-F3B565D647F2Q40080533-96F74B06-6DC2-4A66-A652-33BC7DE49DC0Q41808513-A55ED752-2BB3-43A6-B6DF-41934F7DCA9AQ41843107-0C9134A1-4A56-45C0-8CF0-CE842180CF91Q41962516-88CE6691-C01F-4BE0-B1DD-3FC4AA5D0996Q42321743-311D450B-EAE9-4A73-B0EE-91E6F833403DQ42881041-1EE65B48-396E-4B3D-9298-1D82644D4BC2Q43042596-1F2F3522-3B1D-49EC-9B10-25BCB98DBD2DQ43078241-6BCF1C4E-13C2-40D2-A71F-B132DAC0E72AQ45395361-E6F64947-29C6-420F-83E1-677942BDBD86Q46611126-0CDD164C-E555-4797-8020-C4F3129B4EE2Q48274819-2C291F65-FBD4-4A77-9D1D-52E53FD9402CQ48380461-BD3B5666-C3AB-4907-929E-F0021EFABDEFQ48744925-584A307F-6020-47A5-805A-B77D68B74076Q53255472-AC599F26-5413-41C3-A019-1BB5C674F86F
P2860
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Central nervous system failure ...... eated with imatinib (STI-571).
@en
Central nervous system failure ...... leukemia treated with imatinib
@nl
type
label
Central nervous system failure ...... eated with imatinib (STI-571).
@en
Central nervous system failure ...... leukemia treated with imatinib
@nl
prefLabel
Central nervous system failure ...... eated with imatinib (STI-571).
@en
Central nervous system failure ...... leukemia treated with imatinib
@nl
P2093
P2860
P1433
P1476
Central nervous system failure ...... eated with imatinib (STI-571).
@en
P2093
Daniel E Stepan
John M Ford
Jose F Leis
Peter T Curtin
Richard T Maziarz
Susan Schubach
P2860
P304
P356
10.1080/10428190310001625728
P577
2004-04-01T00:00:00Z